Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,619,694
  • Shares Outstanding, K 72,707
  • Annual Sales, $ 0 K
  • Annual Income, $ -260,760 K
  • EBIT $ -398 M
  • EBITDA $ -413 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.11

Options Overview Details

View History
  • Implied Volatility 41.56% (+2.60%)
  • Historical Volatility 49.15%
  • IV Percentile 11%
  • IV Rank 17.80%
  • IV High 84.44% on 10/31/25
  • IV Low 32.28% on 01/22/25
  • Expected Move (DTE 6) 6.43 (6.13%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 113
  • Put/Call OI Ratio 1.71
  • Today's Open Interest 3,384
  • Open Int (30-Day) 2,997
  • Expected Range 98.37 to 111.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.51
  • Number of Estimates 7
  • High Estimate -1.41
  • Low Estimate -1.69
  • Prior Year -1.05
  • Growth Rate Est. (year over year) -43.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.05 +12.63%
on 11/14/25
112.88 -7.16%
on 11/20/25
+7.77 (+8.01%)
since 11/12/25
3-Month
75.20 +39.36%
on 09/22/25
112.88 -7.16%
on 11/20/25
+24.33 (+30.23%)
since 09/12/25
52-Week
55.53 +88.71%
on 04/09/25
112.88 -7.16%
on 11/20/25
+17.98 (+20.71%)
since 12/12/24

Most Recent Stories

More News
Nuvalent Appoints Ron Squarer to Board of Directors

CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 104.80 (-1.05%)
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 104.80 (-1.05%)
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

NUVL : 104.80 (-1.05%)
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

NDA based on data from global ARROS-1 Phase 1/2 clinical trial

NUVL : 104.80 (-1.05%)
Nuvalent Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

NUVL : 104.80 (-1.05%)
Stocks Retreat on Tech Weakness

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down by -0.83%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -1.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -1.20%....

GOOGL : 309.29 (-1.01%)
AMAT : 259.21 (-4.04%)
AAPL : 278.28 (+0.09%)
MRK : 100.30 (+1.30%)
HP : 29.41 (-4.67%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-055s (-0.25%)
MSFT : 478.53 (-1.02%)
TSLA : 458.96 (+2.70%)
ESZ25 : 6,830.75s (-1.11%)
AMD : 210.78 (-4.81%)
Stock Indexes Slump as the Slide in Tech Stocks Deepens

The S&P 500 Index ($SPX ) (SPY ) today is down by -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -1.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.57%. December E-mini...

GOOGL : 309.29 (-1.01%)
AMAT : 259.21 (-4.04%)
AVGO : 359.93 (-11.43%)
MRK : 100.30 (+1.30%)
$IUXX : 25,196.73 (-1.91%)
UNH : 341.84 (+1.52%)
ELV : 359.07 (-0.32%)
ZNH26 : 112-055s (-0.25%)
MSFT : 478.53 (-1.02%)
TSLA : 458.96 (+2.70%)
ESZ25 : 6,830.75s (-1.11%)
QCOM : 178.29 (-1.64%)
Stocks Fall on Tech Stock Weakness and Disappointing Home Depot Earnings

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.90%. December E-mini...

GOOGL : 309.29 (-1.01%)
AMAT : 259.21 (-4.04%)
AAPL : 278.28 (+0.09%)
B : 43.09 (-0.14%)
MRK : 100.30 (+1.30%)
$IUXX : 25,196.73 (-1.91%)
ZNH26 : 112-055s (-0.25%)
MSFT : 478.53 (-1.02%)
TSLA : 458.96 (+2.70%)
ESZ25 : 6,830.75s (-1.11%)
QCOM : 178.29 (-1.64%)
AMD : 210.78 (-4.81%)
Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

NUVL : 104.80 (-1.05%)
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 104.80 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 110.99
2nd Resistance Point 109.24
1st Resistance Point 107.02
Last Price 104.80
1st Support Level 103.05
2nd Support Level 101.30
3rd Support Level 99.08

See More

52-Week High 112.88
Last Price 104.80
Fibonacci 61.8% 90.97
Fibonacci 50% 84.21
Fibonacci 38.2% 77.44
52-Week Low 55.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar